Childhood Vaccines Market: By Vaccine Type, By Route of Administration, By Application, By Composition, By End-user and Region Forecast 2020-2031
Childhood Vaccines Market size was valued at US$ 58.26 billion in 2024 and is expected to reach US$ 103.14 billion by 2031, growing at a significant CAGR of 8.5% from 2025-2031. Increase in the awareness regarding vaccination of various diseases in developed countries, initiations took by various government and non-governmental organizations such as World Health Organization (WHO), and Centre for Disease Control and Prevention (CDC), and growth in adoption of vaccines fuel the market growth over the forecast period.
Furthermore, government insurance and reimbursement scenario, low cost of vaccines, development of new vaccines for various diseases, and an increase in the healthcare expenditure might boost the market growth over the forecast period. However, adverse effects associated with the vaccines, stringent regulatory policies, and lack of awareness regarding the diseases and vaccination in low-income countries might hamper the growth of market over the forecast period. Vaccines are the biological preparations which provide the active acquired immunity to the particular disease.
Generally, the vaccines contain a substance that resembles the disease causing agent, and is prepared from killed or weakened form of microbe, its toxin or its surface proteins. Agents present in the vaccines stimulate the immune system of the body for recognition of the agent as foreign so that the body's immune system can easily recognize and destroy any of these microorganisms that it later encounters. Childhood vaccines are commonly administered to the age group of 3-8 years which may include DPT vaccine for Diphtheria, Pertussis, and Tetanus, Hepatitis, Influenza, and Measles vaccines, among others.
Study Period
2025-2031Base Year
2024CAGR
8.5%Largest Market
North-AmericaFastest Growing Market
Asia-Pacific
Nowadays, the global childhood vaccines market is in the mature stage, competitors are focusing on the development of new vaccines for various diseases. Increase in the prevalence of various diseases such as measles, hepatitis, diphtheria, and among others might fuel the growth of the market. Acquisitions & mergers, collaborations, launch of new products, and technological developments are some of the key strategies followed by various companies for increasing their share in the global market over the forecast period.
For instance, in January 2011, Sanofi Pasteur has inked a licensing deal with Germany's Organobalance that gives Sanofi access to a modified yeast strain for use in vaccines. Similarly, in October 2014, MabVax Therapeutics Holdings, Inc., announced that the FDA has granted an orphan drug designation to the Company's vaccine intended for the treatment of the childhood cancer neuroblastoma. In addition, in January 2013 GSK, Biological E partner on childhood vaccine to produce a 6-in-1 vaccine to protect against polio and 5 other diseases. The innovation of single vaccine for multiple diseases might fuel the market growth over the forecast period.
Geographically, the childhood vaccines market has been segmented into the following regions Viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. U.S. market is expected to dominate the North America regional revenue share over the coming years due to burgeoning awareness levels and adoption of state-of-art technologies to the production of vaccines.
North America holds the largest share attributed to increase in the prevalence of various diseases such as pertussis (In 2014, according to the CDC, 28,660 cases of pertussis were reported in the U.S), measles, and hepatitis etc. In addition, increase in the R&D of vaccines, rise in the healthcare expenditure, and favourable reimbursement scenario might fuel the market growth in the North America region.
Europe market holds a dominant share owing to increase in the awareness of vaccination regarding various diseases. For instance, France made that vaccination is mandatory from 2018 because of children are dying of measles (according to the European Centre for Disease Prevention and Control, there were 79 cases of measles reported in France in the first two months of 2017). Increase in the healthcare expenditure and research and development activities boost the market in the Europe. Asia-Pacific is an emergent market for childhood vaccines due to increase in the birth rate, especially in India and China. Increase in adoption for vaccination, and growth in the prevalence of infectious disease might fuel the market growth in Asia-Pacific over the forecast period. Due to less cost of vaccines, Latin America and the Middle East and Africa also hold a significant share in market.
Latin America
Europe
Asia Pacific
Middle East
North America
|
Report Benchmarks |
Details |
|
Report Study Period |
2025-2031 |
|
Market Size in 2024 |
US$ 58.26 billion |
|
Market Size in 2031 |
US$ 103.14 billion |
|
Market CAGR |
8.5% |
|
By Vaccine Type |
|
|
By Route Administration |
|
|
By Application |
|
|
By End User |
|
|
By Region |
|
Download Free Sample Report
The childhood vaccines market size was valued at US$ 58.26 billion in 2024 and is expected to reach US$ 103.14 billion by 2031, growing at a significant CAGR of 8.5% from 2025-2031.
Asia-pacific is the fastest-growing region in the market.
AstraZeneca, Bayer AG, Daiichi Sankyo Company Ltd, Eisai Co Ltd, GlaxoSmithKline Plc., Grupo Praxis Pharmaceutical SA, KaloBios Pharmaceuticals, Inc., Kancera AB, Novartis AG, Laboratorio Elea S.A.C.I.F. y A, Oblita Therapeutics BVBA, Sanofi
| 1.Executive Summary |
| 2.Global Childhood Vaccines Market Introduction |
| 2.1.Global Childhood Vaccines Market - Taxonomy |
| 2.2.Global Childhood Vaccines Market - Definitions |
| 2.2.1.Vaccine Type |
| 2.2.2.Route Administration |
| 2.2.3.Application |
| 2.2.4.End User |
| 2.2.5.Region |
| 3.Global Childhood Vaccines Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global Childhood Vaccines Market Analysis, 2020 - 2024 and Forecast 2025 - 2031 |
| 4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global Childhood Vaccines Market By Vaccine Type, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 5.1. Inactivated Vaccines |
| 5.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Attenuated Vaccines |
| 5.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Toxoid Vaccines |
| 5.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Subunit Vaccines |
| 5.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. Conjugate Vaccines |
| 5.5.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 5.6. Others |
| 5.6.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.6.3. Market Opportunity Analysis |
| 6.Global Childhood Vaccines Market By Route Administration, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 6.1. Oral |
| 6.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Intramuscular |
| 6.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Intradermal |
| 6.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Subcutaneous |
| 6.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 6.5. Intranasal |
| 6.5.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.5.3. Market Opportunity Analysis |
| 7.Global Childhood Vaccines Market By Application, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 7.1. Diphtheria |
| 7.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Pertussis |
| 7.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Tetanus |
| 7.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Polio |
| 7.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 7.5. Measles |
| 7.5.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.5.3. Market Opportunity Analysis |
| 7.6. Hepatitis-B |
| 7.6.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 7.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.6.3. Market Opportunity Analysis |
| 7.7. Others |
| 7.7.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 7.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.7.3. Market Opportunity Analysis |
| 8.Global Childhood Vaccines Market By End User, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 8.1. Hospitals |
| 8.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Clinics |
| 8.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Vaccination Centres |
| 8.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 9.Global Childhood Vaccines Market By Region, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 9.1. North America |
| 9.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 9.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.1.3. Market Opportunity Analysis |
| 9.2. Europe |
| 9.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 9.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.2.3. Market Opportunity Analysis |
| 9.3. Asia Pacific (APAC) |
| 9.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 9.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.3.3. Market Opportunity Analysis |
| 9.4. Middle East and Africa (MEA) |
| 9.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 9.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.4.3. Market Opportunity Analysis |
| 9.5. Latin America |
| 9.5.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 9.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.5.3. Market Opportunity Analysis |
| 10.North America Childhood Vaccines Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 10.1. Vaccine Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Inactivated Vaccines |
| 10.1.2.Attenuated Vaccines |
| 10.1.3.Toxoid Vaccines |
| 10.1.4.Subunit Vaccines |
| 10.1.5.Conjugate Vaccines |
| 10.1.6.Others |
| 10.2. Route Administration Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Oral |
| 10.2.2.Intramuscular |
| 10.2.3.Intradermal |
| 10.2.4.Subcutaneous |
| 10.2.5.Intranasal |
| 10.3. Application Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.Diphtheria |
| 10.3.2.Pertussis |
| 10.3.3.Tetanus |
| 10.3.4.Polio |
| 10.3.5.Measles |
| 10.3.6.Hepatitis-B |
| 10.3.7.Others |
| 10.4. End User Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1.Hospitals |
| 10.4.2.Clinics |
| 10.4.3.Vaccination Centres |
| 10.5. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.5.1.United States of America (USA) |
| 10.5.2.Canada |
| 11.Europe Childhood Vaccines Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 11.1. Vaccine Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Inactivated Vaccines |
| 11.1.2.Attenuated Vaccines |
| 11.1.3.Toxoid Vaccines |
| 11.1.4.Subunit Vaccines |
| 11.1.5.Conjugate Vaccines |
| 11.1.6.Others |
| 11.2. Route Administration Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Oral |
| 11.2.2.Intramuscular |
| 11.2.3.Intradermal |
| 11.2.4.Subcutaneous |
| 11.2.5.Intranasal |
| 11.3. Application Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.Diphtheria |
| 11.3.2.Pertussis |
| 11.3.3.Tetanus |
| 11.3.4.Polio |
| 11.3.5.Measles |
| 11.3.6.Hepatitis-B |
| 11.3.7.Others |
| 11.4. End User Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1.Hospitals |
| 11.4.2.Clinics |
| 11.4.3.Vaccination Centres |
| 11.5. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.5.1.Germany |
| 11.5.2.France |
| 11.5.3.Italy |
| 11.5.4.United Kingdom (UK) |
| 11.5.5.Spain |
| 12.Asia Pacific (APAC) Childhood Vaccines Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 12.1. Vaccine Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Inactivated Vaccines |
| 12.1.2.Attenuated Vaccines |
| 12.1.3.Toxoid Vaccines |
| 12.1.4.Subunit Vaccines |
| 12.1.5.Conjugate Vaccines |
| 12.1.6.Others |
| 12.2. Route Administration Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Oral |
| 12.2.2.Intramuscular |
| 12.2.3.Intradermal |
| 12.2.4.Subcutaneous |
| 12.2.5.Intranasal |
| 12.3. Application Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Diphtheria |
| 12.3.2.Pertussis |
| 12.3.3.Tetanus |
| 12.3.4.Polio |
| 12.3.5.Measles |
| 12.3.6.Hepatitis-B |
| 12.3.7.Others |
| 12.4. End User Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1.Hospitals |
| 12.4.2.Clinics |
| 12.4.3.Vaccination Centres |
| 12.5. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.5.1.China |
| 12.5.2.India |
| 12.5.3.Australia and New Zealand (ANZ) |
| 12.5.4.Japan |
| 12.5.5.Rest of APAC |
| 13.Middle East and Africa (MEA) Childhood Vaccines Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 13.1. Vaccine Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1.Inactivated Vaccines |
| 13.1.2.Attenuated Vaccines |
| 13.1.3.Toxoid Vaccines |
| 13.1.4.Subunit Vaccines |
| 13.1.5.Conjugate Vaccines |
| 13.1.6.Others |
| 13.2. Route Administration Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1.Oral |
| 13.2.2.Intramuscular |
| 13.2.3.Intradermal |
| 13.2.4.Subcutaneous |
| 13.2.5.Intranasal |
| 13.3. Application Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1.Diphtheria |
| 13.3.2.Pertussis |
| 13.3.3.Tetanus |
| 13.3.4.Polio |
| 13.3.5.Measles |
| 13.3.6.Hepatitis-B |
| 13.3.7.Others |
| 13.4. End User Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.4.1.Hospitals |
| 13.4.2.Clinics |
| 13.4.3.Vaccination Centres |
| 13.5. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.5.1.GCC Countries |
| 13.5.2.South Africa |
| 13.5.3.Rest of MEA |
| 14.Latin America Childhood Vaccines Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 14.1. Vaccine Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.1.1.Inactivated Vaccines |
| 14.1.2.Attenuated Vaccines |
| 14.1.3.Toxoid Vaccines |
| 14.1.4.Subunit Vaccines |
| 14.1.5.Conjugate Vaccines |
| 14.1.6.Others |
| 14.2. Route Administration Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.2.1.Oral |
| 14.2.2.Intramuscular |
| 14.2.3.Intradermal |
| 14.2.4.Subcutaneous |
| 14.2.5.Intranasal |
| 14.3. Application Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.3.1.Diphtheria |
| 14.3.2.Pertussis |
| 14.3.3.Tetanus |
| 14.3.4.Polio |
| 14.3.5.Measles |
| 14.3.6.Hepatitis-B |
| 14.3.7.Others |
| 14.4. End User Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.4.1.Hospitals |
| 14.4.2.Clinics |
| 14.4.3.Vaccination Centres |
| 14.5. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.5.1.Brazil |
| 14.5.2.Mexico |
| 14.5.3.Rest of LA |
| 15. Competition Landscape |
| 15.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 15.2.1.AstraZeneca |
| 15.2.2.Bayer AG |
| 15.2.3.Daiichi Sankyo Company Ltd |
| 15.2.4.Eisai Co Ltd |
| 15.2.5.GlaxoSmithKline Plc. |
| 15.2.6.Grupo Praxis Pharmaceutical SA |
| 15.2.7.KaloBios Pharmaceuticals, Inc. |
| 15.2.8.Kancera AB |
| 15.2.9.Novartis AG |
| 15.2.10.Laboratorio Elea S.A.C.I.F. y A |
| 15.2.11.Oblita Therapeutics BVBA |
| 15.2.12.Sanofi |
| 16. Research Methodology |
| 17. Appendix and Abbreviations |
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.
Download Sample
